Clinical Trials Logo
  1. Home
  2. Scleroderma, Diffuse
  3. NCT03831438

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

Scleroderma, Diffuse Clinical Trial

Official title:
A Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200: A Transforming Growth Factor β (TGFβ) Inhibitor, in Patients With Diffuse Cutaneous Systemic Sclerosis

Clinical Trial Summary

Several lines of evidence place TGF-β, a potent pro-fibrotic cytokine, at the centre of the pathogenesis of Systemic Sclerosis (SSC). AVID200 is a novel inhibitor of TGF-β ligands. This Phase 1 trial is designed to evaluate the safety, tolerability and preliminary efficacy of AVID200 in SSc patients in order delineate doses to be further evaluated in Phase 2. Approximately 9 to 24 male and female patients with documented SSc (i.e., score ≥ 9 according to the American College of Rheumatology/European League Against Rheumatism classification criteria), and classified as having the diffuse cutaneous SSs (dcSSc) subset (i.e., according to the LeRoy and Medsger Classification), will be entered into this Phase 1a, multicentre, open-label, dose-escalation, cohort study of AVID200.

Clinical Trial Description

The trial is designed to evaluate the safety and tolerability of sequential escalating doses of AVID200 (study drug), in order delineate a potential effective range of tolerated doses to be further evaluated in Phase 2. Patients will be treated and followed on an outpatient basis throughout the trial, unless hospitalization is required for other reasons, or to assure patient safety. The choice of doses for further Phase 2 study will be based on clinical and laboratory data obtained during this trial, including safety, PK, and preliminary anti-fibrotic activity. Upon completion of Cycle 1, and provided re-treatment criteria are met, patients may receive up to 2 additional cycles of study drug unless a criterion for treatment discontinuation has been met. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03831438
Study type Interventional
Source Formation Biologics
Contact
Status Active, not recruiting
Phase Phase 1
Start date January 1, 2019
Completion date January 30, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Completed NCT02503644 - Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis Phase 2
Completed NCT05622578 - Phenotyping of Chronic Pain in Diffused Systemic Scleroderma N/A
Terminated NCT02374320 - Exparel as a Nerve Block for Severe Hand Pain Phase 2/Phase 3
Completed NCT00442611 - A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Phase 1/Phase 2
Not yet recruiting NCT05351060 - Novel Splinting Technique Using 3D Models N/A
Completed NCT04647890 - Effects of FT011 in Systemic Sclerosis Phase 2
Recruiting NCT02682511 - Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Phase 2
Recruiting NCT00428883 - High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis Phase 2/Phase 3
Completed NCT06425653 - Exercise With Scleroderma Functional Outcomes N/A
Not yet recruiting NCT05148598 - ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma Phase 3
Terminated NCT04837131 - A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients Phase 2
Recruiting NCT01347008 - Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Phase 3